The effectiveness of fluoxetine on the treatment of adaptive spasm caused by anxiety
Not Applicable
Not yet recruiting
- Conditions
- Accommodative spasm.Disorders of accommodationH52.5
- Registration Number
- IRCT20240617062160N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
Having eye spasms with symptoms
Bilateral accommodative spasm (there should be conditions in both eyes and it should not be unilateral)
No history of underlying diseases
Absence of strabismus
Exclusion Criteria
Uncorrected hyperopia
Having systemic diseases
Having pathological anxiety
Having eye diseases such as keratoconus, cataract, uveitis, retinal retinopathy, and all diseases that affect the quality of vision and visual system of the patient.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fluoxetine's effect on accommodative spasm related to anxiety?
How does fluoxetine compare to standard-of-care treatments for H52.5 disorders of accommodation?
Are there specific biomarkers that predict response to fluoxetine in anxiety-induced accommodative spasm?
What are the potential adverse events associated with fluoxetine treatment for accommodative spasm?
What combination therapies or alternative drugs show promise for treating anxiety-related accommodative spasm?